· Published by Health Canada · Official notice
Notice about Health Canada advisories
September 8, 2005
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Surgery, Respirology, and other involved professional staff and post this NOTICE in your institution.
Subject: Complications associated with the use and removal of metallic airway stents in patients with benign airway obstruction
Metallic airway stents are being increasingly used in the treatment of patients with benign and malignant airway strictures. They offer many advantages over other stents such as ease of insertion, good conformation to irregular airways and a favourable internal-to-external diameter ratio. Health Canada is aware, however, of international reports of complications related to the use and removal of both covered and uncovered metallic airway stents including those outlined in a U.S. Food and Drug Administration Public Health Notice (July 29, 2005). Patients with benign airway obstruction are believed to be at higher risk because, on average, this group has a longer duration of stent therapy than those with malignant disease. Although no such incidents have been reported to the Health Products and Food Branch Inspectorate, Health Canada wishes to alert healthcare professionals to this information.
Reported complications during stent therapy include recurrent obstructions due to granulation tissue formation (requiring repeated interventions), stenosis at the ends of the stent, stent fracture, infection, stent migration and mucous obstruction. Additional complications associated with the removal of these stents include mucosal tears with bleeding, retention of pieces of metallic stent in the airway lining, the need for postoperative mechanical ventilation and perforation leading to tension pneumothorax. These stents can be removed intact but fracture or failure of the device during the procedure frequently forces a piecemeal removal. Also, further intervention (other types of stents, surgical correction) is required in many cases due to restenosis of the airway.
In order to minimize the risk of these and other complications associated with the use of metallic airway stents, Health Canada recommends the following:
Health Canada has completed a labelling review of the metallic tracheal stents licensed in Canada and will address labelling inadequacies in regulatory letters.
Health Canada depends on health care professionals to report adverse incidents related to medical devices. Any serious and/or unexpected adverse incident related to medical devices should be reported to Health Canada at the following address:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
For other inquiries: please refer to contact information:
Marketed Health Products Directorate (MHPD)
MHPD_DPSC@hc-sc.gc.ca
Tel/Tél : (613) 954-6522
Fax/Télé : (613) 952-7738
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.